The Role of Vitamin D3 in Pediatric Bronchiectasis Severity
The Role of Vitamin D3 in Pediatric Bronchiectasis Severity
Vitamin D3 therapy was effective in decreasing the frequency of pulmonary exacerbations and
 preserving lung functions , thereby improving the disease severity even more in non CF than
 CF bronchiectasis patients
Objectives: To compare the effect of vitamin D3 on modifying the disease severity in CF and
 non CF bronchiectasis pediatric patients.

 Patients and Methods: This was a randomized clinical trial evaluating the role of oral
 vitamin D3 supplementation for 6 months in forty patients with CF and non CF bronchiectasis
 under the age of 18 years with vitamin D deficiency or insufficiency . The primary outcome
 was to reach the sufficient Vitamin D level. The secondary outcome was to follow up the
 frequency of pulmonary exacerbations and lung function after vitamin D3 supplementation.
Inclusion Criteria:

 -  ages less than 18 years .

 -  Patients with documented diagnosis of CF (by the presence of a twice positive sweat
 chloride test and or paired CFTR DNA genetic mutations).

 -  Patients with non CF bronchiectasis diagnosed clinically and radiologically ( sweat
 chloride test negative) with a high resolution CT-confirmed diagnosis and clinical
 history consistent with bronchiectasis .

 -  Vitamin D deficient or insufficient CF and non CF bronchiectasis patients

 Exclusion Criteria: if they had

 -  sufficient Vitamin D level .

 -  chronic lung diseases other than CF and non CF bronchiectasis , liver or renal
 diseases.

 -  reported taking vitamin-D supplements or steroid therapy in the last 6 weeks.